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Abstract

ROLE OF SRSF3 IN CONTROL OF ALTERNATIVE SPLICING OF CPEB2 IN TRIPLE
NEGATIVE BREAST CANCER
by
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Thesis Director: CHARLES E. CHALFANT
Professor, Department of Biochemistry and Molecular Biology

In the presented study, we identified that SRSF3 controls the alternative splicing
of CPEB2 and consequently promotes a metastatic phenotype in triple negative breast
cancer (TNBC). TNBC causes thousands of deaths annually, frequently due to a lack of
effective treatments and a high rate of metastasis in patients. Alternative splicing has
been found to be dysregulated in numerous cancers, while splicing factors such as
SRSF3 are variably expressed. In this study we performed a siRNA panel to screen
potential splicing factors, then used specific siRNA to study the effect of its knockdown
on cellular function. These results showed that SRSF3 encourages the production of the
pro-metastatic isoform of CPEB2, which contributes the aggressive phenotype of the

ix

x

tumor. We utilized numerous methods to measure the metastatic function of cultured
TNBC cells to determine if SRSF3 strongly promoted the metastatic function. These data
showed that siRNA reduction of SRSF3 was able to reduce the metastatic potential of
cancer cells. These findings suggest that SRSF3 has great potential as a therapeutic
measure to reduce and minimize the aggressiveness of TNBC tumors.
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CHAPTER 1
BACKGROUND

1.1 Cancer
Cancer is a terrible disease that affects millions of Americans every year. In 2014,
1,665,540 Americans were diagnosed with some form of cancer [1]. Second in numbers
to only heart disease, cancer kills numerous Americans annually. According to the
National Cancer Institute, 35.2% of patients diagnosed with cancer die annually [1]. In
2014, cancer accounted for 585,720 deaths in the United States [1]. Cancer’s high
mortality rate is due to the heterogeneity of tumors and the lack of effective treatment
methods.
Breast cancer is the most commonly diagnosed form of cancer, with 235,030
diagnoses in 2014 [1] (Figure 1-1). Additionally, breast cancer is the third most deadly
type of cancer, causing 40,430 deaths in the US in 2014 [1] (Figure 1-1). As medical
treatments have improved, both the mortality rates and the recurrence rates for breast
cancer have dropped significantly. Yet, until we find a cure, there is still room for further
progress. As of 2011, the breast cancer mortality rate is 17.2%, representing the
percentage of diagnosed patients that died during treatment [1]. Similarly, the 5-year
survival rate is only 91.8%, demonstrating that breast cancer tumors tend to readily
metastasize or develop resistance to current therapies [1]. The cases in which current
treatments are most ineffective belong to one of two particular subtypes of breast cancer:
triple negative breast cancer (TNBC) and HER2 positive breast cancer. Both of these
cancers tend to be particularly metastatic and lack targeted treatment options [2].

2

CANCER DIAGNOSES (2014)
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Figure 1-1. Cancer diagnoses and deaths in 2014. According to the National Cancer
Institute, breast cancer is the most commonly diagnosed cancer subtype. 235,030 new
cases of breast cancer were reported in 2014. Additonally, breast cancer is the third
leading cause of cancer deaths. 40,430 deaths in 2014 were attributed to breast cancer.
Source: SEER 2014 [1]
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Cancer
Subtype

New Cases in
2014

Deaths in
2014

5 Year
Survival Rate
(%)

Breast

235,030

40,430

91.8

Prostate

233,000

29,480

99.8

Lung

224,210

159,260

18.2

Colon

96,830

50,310

66.5

Pancreas

46,420

39,590

7.2

Table 1-1. Cancer Statistics. Breast cancer is the most commonly diagnosed form of
cancer in the United States. It is also responsible for the third highest number of cancerrelated deaths per year. Despite that, the 5 year survival rate for breast cancer is high
(91.8%), but still provides room for improvement. This table compares diagnoses, deaths,
and survival rates to four other prominent forms of cancer. Source: SEER 2014 [1]
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1.1.1 Process of Cancer Metastasis
One of the most dangerous aspects of cancer is its ability to metastasize to other
areas in the body. This process makes cancers very challenging to treat, even if surgery
effectively resects the tumor.
To better understand metastasis, scientists have broken down the process into five
general stages (Figure 1-2). The first of these stages is initial tumor proliferation and local
invasion (growth). During this stage, the tumor grows into local tissues while accumulating
mutations that promote growth and cell-cycle progression. The next stage is intravasation,
when individual tumor cells slough off into the circulating blood system. At this point, most
tumor cells undergo epithelial to mesenchymal transition (EMT) to encourage anchorage
independent growth [3]. In general, when the cells are no longer attached to the
extracellular matrix or other epithelial cells, the cells will experience detachment-induced
cell death (anoikis) signaling. In the case of cancer, if the tumor cells have not acquired
sufficient mutations to resist this apoptotic signaling, the tumor cells will not survive
intravasation. After the third stage, migration, the tumor cells will reach the site of
metastasis and undergo extravasation. During extravasation, the tumor cells invade the
walls of the capillaries and surrounding tissue in the new location. The cells will now
undergo mesenchymal to epithelial transition (MET) to encourage accelerated cellular
growth in an anchorage-dependent manner [3]. This final stage is referred to as
colonization and is where the new tumor gains size and tumor cells multiply.
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Extravasation
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Figure 1-2. Schematic Representation of the Stages of Cancer Metastasis. There
are five steps that occur during tumor metastasis. 1) Growth: tumor grows in size in initial
location until it acquires sufficient mutations to metastasize. 2) Intravasation: cells from
the initial tumor detach from the surrounding tissue, undergo EMT, and enter the
circulatory system. 3) Migration: cells travel through the body’s vasculature. 4)
Extravasation: cells invade site of distant metastasis. 5) Colonization: cells undergo MET
to promote anchored cell growth.
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1.1.2 Triple Negative Breast Cancer
There is a significant clinical need to improve treatments for the triple negative
subtype of breast cancer (TNBC) due to the high mortality rates and high rates of
recurrence associated with this cancer. The term triple negative refers to a subtype of
breast cancer tumors that do not express the estrogen, progesterone, and HER2
receptors [2,4]. While only 15-20% of all breast cancers are triple negative, they account
for almost 70% of the eventual deaths, either due to recurrence or resistance to standard
therapies [1,2].
Data analyses have shown that TNBC has a hazard ratio (relative mortality rate
between TNBC and standard breast cancer) of 4.35 [1]. Due to a lack of a specific or
unique drug target, less effective broad spectrum treatments must be used [4]. Common
treatment strategies include the use of antracyclines, taxanes, ixabepilone, platinum
agents, select biological agents, and anti-EGFR drugs [4-7].
Initially, patients with TNBC will appear to respond well to treatment, but will
ultimately suffer a worse long term prognosis [4]. It appears that tumor cells in TNBC
patients are able to develop metastatic characteristics that allow them to avoid complete
eradication by standard treatment methods. Despite breast cancer having a 91.8% 5-year
survival rate, patients with TNBC only exhibit a 30.0% 5-year survival rate, demonstrating
a dramatic need for clinical improvement [1,2].
Currently, there are a few commonly used in vitro models of TNBC that utilize
human tumor cells cultured for study (e.g. MDA-MB-231, MDA-MB-468, BT549,
SUM1315) [8]. These cell lines were acquired from patient tumors and cultured to ensure
accurate representation of the initial tumor. Researchers frequently use these models in
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conjunction with mouse models to observe the effects of various treatments on the
metastatic functionality of the TNBC cells [4]. Mouse models provide in vivo models of
TNBC that allow system wide observation of metastasis in a controlled setting. In vivo
models can be used to test potential drug treatments that could potentially be translated
to human clinical trials in the future.

1.1.3 HER2/ErbB2 Positive Breast Cancer
Like TNBC, HER2 positive breast cancer lacks effective clinical treatments due to
its aggressive and metastatic nature. HER2 positive breast cancers overexpress the
membrane protein ErbB2/HER2 and tend to yield poor patient prognoses [2]. The
National Cancer Institute determined that patients with HER2 positive breast cancer have
a hazard ratio of 3.60, rating as the second most dangerous subtype of breast cancer [1].
Overexpression of ErbB2/HER2 accumulates at the plasma membrane and leads
to chronic activation of the ErbB2 survival intracellular signaling pathways [2]. These
pathways include Src, STAT3, PI3K, and MAPK, and all promote metastatic
characteristics such as proliferation, survival, motility, and tissue invasion [2]. Enhanced
signaling may occur because activated ErbB2 is recycled to the plasma membrane of the
cell instead of undergoing lysosomal proteolysis [2]. Lack of precise understanding of this
phenomenon presents a challenge in designing targeted treatments.
To gain greater understanding of HER2 positive breast cancer, researchers have
developed a number of models to study the disease. Numerous patient samples have
been acquired and repurposed to function as cellular models of HER2 positive breast
cancer models (e.g SKBR3, MDA-MB 453) [8]. These cell lines do not express the other
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two receptors (estrogen and progesterone) and consequently only highly express
ErbB2/HER2. Similar to TNBC models, HER2 positive cell lines are commonly used in
conjunction with animal models to study systemic metastasis. This can be performed
through the use of tumor xenografts or tissue specific injections to act as an in vivo model
[8].

1.2 Alternative mRNA Splicing
Alternative RNA splicing is a mechanism that contributes to the incredible diversity
of protein messages produced by a single cell. Through this mechanism, RNA sequences
can be altered through the inclusion or exclusion of certain RNA exons at specific splice
sites [9,10]. Variants of the same protein that differ by selective inclusion of exons are
referred to as isoforms of the protein and can have a wide range of cellular functions,
despite sequence similarities (Figure 1-3). Splice sites are binding sites for the
spliceosome, a protein complex that produces the newly spliced mRNA sequence.
The actions and interactions between cellular splicing factors and RNA sequences
control the selection of the splicing sites. [10,11]. Splicing factors are RNA-binding
proteins that recognize particular RNA motifs to either guide (enhancers) or block
(silencers) the spliceosome [9,10]. The action of the splicing factors allows for the vast
genetic diversity of an organism, while only using a small portion of the genome.
According to Guttmacher and Collins, the mechanism of alternative splicing gives cells
the ability to encode over 100,000 proteins using only 30,000 genomic bases [12].
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Figure 1-3. Mechanism of Alternative Splicing. During alternative splicing, gene exons
are selectively incorporated to produce mature mRNA for translation into proteins.
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1.2.1 SR Splicing Factor Family
The cellular function of the SR family of exonic splicing enhancers is to regulate
selection of alternative splice sites to promote inclusion of exons into the finalized
sequence [10,11]. The SR family of splicing factors antagonizes the activity of the hnRNP
family of exonic splicing silencers, preventing them from promoting the removal of mRNA
exons [11]. SR proteins are made of one or two N-terminal RNA recognition motifs (RRM)
followed by a downstream arginine/serine-rich (RS) domain characterized by consecutive
RS or SR repeats [11]. The RRM provides substrate specificity of the particular SR protein
with its target short mRNA splicer enhancer sequence [11] (Figure 1-4). As a result, each
SR protein interacts with a very specific set of proteins, typically to promote a particular
function. SR proteins are involved in many processes of gene regulation, including RNA
maturation, transport, and translation [10,13]. Thus, the SR family of proteins plays
important roles in alternative splicing and subsequent cellular signaling.
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Figure 1-4. General Structure of SR Protein Family. All SR protein family members
contain N-terminal RNA-binding domains (RRM’s) and C-terminal arginine/serine-rich
domains (RS’s). The number and length of these domains vary between SR family
members.
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1.2.2 SRSF3 / SRp20
SRSF3, also known as SRp20, is a member of the SR family of splicing factors.
Multiple studies implicate SRSF3 to have a role in protein translation, mRNA
polyadenylation, as well as numerous other cellular pathways important for cellular
growth,

EMT

transition,

and

RNA

processing

[10,11,14,15].

Cancers

show

overexpression of SRSF3, suggesting that it might exhibit an important role in growth
control [15]. Jia et al. also found that increased levels of SRSF3 are a critical step for
tumor initiation, progression, and maintenance [15].
Stickeler et al. showed that there was a positive correlation between high levels of
SRSF3 and a higher severity of mammary tumorigenesis [16]. He et al. showed that cells
with reduced SRSF3 expression grow slowly, are not resistant to anoikis, and will readily
undergo apoptosis proportional to the reduction in SRSF3 [17]. Other studies have
implicated dysregulation of SRSF3 with alternative splicing of p53, a known tumor
suppressor commonly mutated in all cancer types [18]. While research connects SRSF3
and cancer, the mechanism has not been conclusively determined.

1.3 Cytoplasmic Polyadenylation Element Binding Protein 2 (CPEB2)
CPEB2 is a member of the CPE family of cytoplasmic polyadenylation proteins
responsible for control of protein translation [19-21]. This family of proteins has distinctive
RNA recognition motifs and C-terminal zinc finger domains to allow specific interaction
with U-rich mRNA elements [19-21]. Through binding of mRNA, CPEB2 stimulates the
complete polyadenylation of immature mRNA and promotes the formation of the ribosome
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by specifically recruiting eIF4F, one of the first components needed to initiate protein
translation [19-21].
Research shows that CPEB2 exhibits substrate specificity, interacting with
TWIST1 directly and HIF1α via eEF2 [19,22,23]. Signaling factors TWIST1 and HIF1α
are frequently mutated in cancers, suggesting a correlation between these two
observations. In addition, CPEB mRNAs appear to be downregulated in numerous tumor
samples, suggesting that cancer cells lose their ability to regulate translation [19]. Hagele
et al. researched the interconnectedness between CPEB2 and HIF1α and determined
that CPEB2 has an inverse relationship with the activation of HIF1α [21]. Through its
control of HIF1α mRNA, CPEB2 may be involved in cancer malignancy, but this has not
been experimentally confirmed [19]. Studies have shown organ specific patterns of CPE
activation, suggesting tissue specific functionality of CPEB2 [21].
In addition to its downstream action, numerous groups have looked into alternative
roles of methods of CPE activation and consequent effects. Research by Di Nardo et al.
suggests that CPEB2 may also promote a polyadenylation function after stimulation from
the mechanistic target of rapamycin (mTOR) pathway [24]. The mTOR pathway is
naturally activated by cellular stresses such as hypoxia or insulin [21]. Other studies show
that different phosphorylation pathways, including phosphoinositide 3-kinase GSK3, the
aurora A kinase, and the CDC2 pathways are associated with activation of CPEB [25].
Wang et al. shows that CPEB2 has multiple isoforms due to the inclusion of
particular exons in the mature mRNA [26]. These various isoforms have different
functions based on their substrate specificity and complete 3-dimensional structure. The
most common isoforms of CPEB2 are the A and B isoforms. As shown in Figure 1-5, they
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differ only through the inclusion of exon 4, which is retained in CPEB2B. Preliminary data
suggest that the B isoform of CPEB2 promotes metastatic activity in cells, which
commonly produces an extremely aggressive cancerous tumor [27]. Through greater
understanding of the alternative splicing action between the isoforms of CPEB2, we hope
to be able to develop more effective patient treatments for the future.

15

Figure 1-5. Alternative Splicing of CPEB2. The two most common isoforms of CPEB2
differ only by the inclusion of exon 4. The splicing factor that controls this interaction is
not yet known.
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CHAPTER 2
DETERMINATION OF CPEB2 SPLICING FACTOR

2.1 Introduction
While much research has gone into understanding the mechanisms that cause
cancer and cancer metastasis, there are still many gaps in our knowledge. One of the
stages in cancer metastasis is the development of anoikis resistance, which allows cells
to travel through the vasculature of the body to colonize in other locations of the body.
This is one of the events that make many cancers very difficult to treat via traditional
surgical techniques. As a result, there is great clinical interest for any methods that reduce
the ability of a tumor to develop anoikis resistance. One of the less explored ways to study
metastasis is through investigating alternative splicing of signaling molecules. By gaining
an understanding of how these upstream pathways act in cancer, one could alter splicing
to prevent the development of cancer.
Studies by our laboratory have investigated the role of cytoplasmic polyadenylation
element binding protein 2 (CPEB2) in promoting a metastatic phenotype in triple negative
breast cancer. We have shown that the splicing of CPEB2 is altered in triple negative
breast cancer patients to produce a higher abundance of the larger isoform (B) of CPEB2
[28]. Further research has shown that CPEB2B seems to promote cell growth when
endogenously expressed in MDA MB 231 Par cells, while CPEB2A does not promote the
same growth [28]. With further study, preventing CPEB2B splicing could be used as a
very promising anti-metastatic cancer therapy. Due to the fact that CPEB2 has low basal
expression in non-tumorigenic cells, it could be used as a targeted therapy to only affect
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cancerous cells. This has great therapeutic potential and is therefore a worthwhile
strategy for research.

2.2 Materials and Methods
2.2.1 Cell Culture
The lab acquired MDA MB 231 parental TNBC cells (231 Par) from ATCC. They
were cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen) and 1% penicillin/streptomycin (BioWhittaker) at 5% CO2 and at 37°C. When
the 231 Par cells reached 70% confluence, they were passaged to a maximum passage
number of 9. MDA MB 231 anoikis resistant TNBC cells (231 AnR) were acquired by
plating 231 Par cells on 10cm2 culture dishes coated with 20 mg/mL poly(2-hydroxyethyl
methacrylate) (polyhema) (Sigma-Aldrich) for at least 3 passages on polyhema-coated
plates.

2.2.2 Proteomics Study
In order to identify splicing factors that regulate alternative splicing of CPEB2, we
chose to investigate exon 4 interactions (the exon included in CPEB2B). First, we
collected nuclear extracts from 231 AnR cells in standard culture conditions. Next, we
added either specific or non-specific competitor sequences (Dharmacon) to the samples
to act as loading controls. After that, we combined the samples with FITC-conjugated
exon 4 of CPEB2 (Dharmacon). Next, the samples were run on a DNA polyacrylamide
gel until bands were visible. We performed selective excision of the visible bands and
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sent these samples to The Ohio State University proteomics core for analysis to
determine interactions with known splicing factors. After analysis, we received a list of
interacting proteins to the query region. Using online protein databases, we were able to
determine which results were potential splicing factors to experimentally test.

2.2.3 siRNA Panel of Candidates
Candidate splicing factors as determined above were experimentally tested to
observe their effect on CPEB2 alternative splicing. The lab purchased commercially
available Silencer siRNA (Ambion by Life Technologies) for SRFS3, hnRNPA2B1,
hnRNPF, hnRNPH1 and reconstituted to 20 µM. 231 Par (2 x 105) were plated on 6 well
tissue culture plates (Costar) in appropriate media as described previously. We added
siRNA at a concentration of 25 nM in accordance to Dharmafect protocol (GE
Healthcare). After 6 hours, cell media was replaced. We harvested cells after 48 hours to
ensure maximal siRNA effect.

2.2.4 Western Blot Analysis
Quick-Start Bradford Reagent (Bio-Rad) was used to determine the protein
concentration of the samples for consistent protein gel loading. We added 10 ug of each
sample to a 7.5% polyacrylamide gel (Bio-Rad) and run at 60 mV for 3 hours in 1X
Tris/Glycine/SDS buffer (Bio-Rad). The gel was transferred to a PVDF membrane for 2
hours in transfer buffer (70 H20 : 20 MeOH : 10 10X Tris/Glycine Buffer (Bio-Rad)). After
transfer, the membranes were blocked in 5% milk for 30 minutes at room temperature
and washed 3 times in wash buffer (1X PBS + 0.1% Tween-20) for 5 minutes each. Next,
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the membranes were incubated in primary antibody diluted in 5% milk (Actin 1:8000,
SRSF3 1:1000, CPEB2 1:1000) overnight at 4°C. The following morning, we washed the
membranes 3 times in wash buffer (1X PBS + 0.1% Tween-20) for 5 minutes each and
then incubated in the appropriate secondary antibody (Actin-Mouse 1:8000, SRSF3Rabbit 1:1000, CPEB2-Rabbit 1:1000) for 1 hour at room temperature. Following
secondary antibody incubation, the membranes were washed 3 times in wash buffer (1X
PBS + 0.1% Tween-20) for 5 minutes each and then developed the membranes using
SuperSignal Pico Developing Solution Reagents (Thermo) and imaged using a film
developer.

2.3 Results
2.3.1 Proteomics Panel
After determination that alternative splicing of CPEB2 affects the metastatic
potential of triple negative breast cancer cells, the next logical step was to determine what
splicing factor(s) control(s) this action [27]. In order to do this, we ran samples on a DNA
polyacrylamide gel as described in 2.2.2. We selectively excised distinct gel bands as
shown in Figure 2-1. Results from The Ohio State University provided a list of proteins
that bound to exon 4 of CPEB2 (the exon alternatively spliced between the A and B
isoforms of CPEB2). This list provided numerous candidates that interacted with the
region of interest. (Figure 2-1). We recognized many of these candidates as artifacts of
the proteomics screen and discounted them. As a result, the remaining candidate factors
to examine were SRSF3, hnRNP A2B1, hnRNP A0, hnRNP F, and hnRNP H1. All are
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known splicing factors that have been shown to be dysregulated in cancer. These results
directed our studies to investigate the specific roles of those factors in MDA MB 231 cell
metastasis.

FITC-CPB + SC

FITC-CPB+NSC
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Bands for excision

Figure 2-1. EMSA Allows Selective Excision of Exon 4 Binding Factors. Nuclear
extracts from 231 AnR cells were added to FITC-conjugated exon 4 of CPEB2. The
mixture was run on a DNA polyacrylamide gel until distinct bands were visible. Individual
bands were excised and sent to The Ohio State University for proteomics analysis.
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2.3.2 siRNA Panel of Candidates
To investigate the role of a particular splicing factor in alternative splicing of
CPEB2, we chose to use siRNA to knockdown each of the potential splicing factors and
observe the effect on the relative abundance of the splice variants of CPEB2. We used a
siRNA cocktail specific to each candidate splicing factor as well as combining the siRNAs
for hnRNP H1 and hnRNP F as they have been shown to react cooperatively in the
literature. The results show a marked decrease in the B isoform of CPEB2 when treated
with siRNA specific to SRSF3 while other siRNAs did not show a significant effect on
CPEB2 splicing (Figure 2-2). Comparing the ratios of the two splice variants allows clear
visualization of the effect of knocking down SRSF3 on CPEB2 alternative splicing. Use of
the CPEB2 A:B ratio provides a means of distinguishing the alternative splicing of CPEB2
and allows quantification of the observation. As the relative abundance of the pro-growth
isoform (B) decreases, the A:B ratio will increase. Samples with a high A:B ratio are less
metastatic and easier to treat. These results suggest that SRSF3 mediates CPEB2
alternative splicing and that it causes an increase in the pro-survival B isoform of CPEB2.

si hnRNP H1

si hnRNP F

si hnRNP H1

si SRSF3

siRNA Control

No Treatment
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B
A

CPEB2
Actin
Ratio A:B

7.40

6.96

19.0

9.78

7.06

3.58

Figure 2-2. siRNA Panel of Alternative Splicing of CPEB2. 231 Par cells were treated
with siRNA (25 nM) for 6 hours, then media was replaced. After 48 hours, the cells were
collected and analyzed via western blot for isoforms of CPEB2. Densitometry was
performed on the A and B isoforms of CPEB2 as indicated with arrows. The ratio of the
densitometry results were calculated for each sample.
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2.3.3 Western Blot Analysis
After completion of the siRNA screen, we chose to verify that reduction of SRSF3
causes a change in alternative splicing in both 231 Par and 231 AnR cells. As shown in
Figure 2-3, treatment with siRNA for SRSF3 reduces the amount of the B isoform and
consequently increases the A:B ratio of those samples. One can also see that the 231
Par cells basally have a higher A:B ratio than 231 AnR cells. The differences are more
pronounced in the 231 Par because of their naturally lower levels of the B isoform. This
reflects the metastatic nature of the 231 AnR cell line.
We also chose to examine the levels of SRSF3 expressed in 231 Par and 231 AnR
cells to see if the more metastatic nature of 231 AnR cells correlated with SRSF3 levels.
Figure 2-4 shows that 231 AnR cells overexpress SRSF3 compared to 231 Par.
Additionally, treatment with siSRSF3 causes significant reduction in SRSF3 in both cell
lines, restoring 231 AnR SRSF3 levels to that of basal 231 Par cells. This suggests that
alteration of SRSF3 occurred during the acquisition of anoikis resistance in these cell
lines.
In order to more effectively study the effects of SRSF3 knockdown, we looked to
optimize knockdown of SRSF3 to provide the most dramatic effects to the cells. We took
the components of the purchased siRNA cocktail and tested each of the 3 siRNAs
individually to determine which provided the greatest effect on reducing SRSF3
expression. We were able to quantify this knockdown using densitometry to compare the
relative intensity of SRSF3 to Actin. As shown in Figure 2-5, the second and third siRNA
components provided the greatest reduction in SRSF3 expression and consequently the
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lowest SRSF3:Actin ratio. As a result, future experiments used a combination of siRNAs
2 and 3 to knockdown SRSF3.
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CPEB2
Actin
A:B Ratio

2.57

8.33

1.62

3.35

Figure 2-3. Knockdown of SRSF3 Causes Decrease in CPEB2B. 231 Par and 231
AnR cells were treated with siRNA (25 nM) for 6 hours, then media was replaced. After
48 hours, the cells were collected and analyzed via western blot for isoforms of CPEB2.
Densitometry was performed on the A and B isoforms of CPEB2. A:B ratios were
performed for each sample and averaged within treatment groups.
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Figure 2-4. SRSF3 is Upregulated in Anoikis Resistant Cells. 231 Par and 231 AnR
cells were treated with siRNA (25 nM) for 6 hours, then media was replaced. After 48
hours, the cells were collected and analyzed via western blot for knockdown of SRSF3.
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0.54

0.40
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SRSF3
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Densitometry:

Figure 2-5. Selective Components of siSRSF3 Promote Greatest SRSF3 Reduction.
231 Par cells were treated with individual siRNA components (25 nM) for 6 hours, then
media was replaced. After 48 hours, the cells were collected and analyzed via western
blot for knockdown of SRSF3.
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2.4 Discussion
Analysis of our results provides some important insights into the mechanisms that
are altered in triple negative breast cancer. From a panel of potential candidate splicing
factors, we determined that SRSF3 not only affected the alternative splicing of CPEB2,
but also promoted the expression of CPEB2B, the more metastatic isoform of the protein.
This was further supported by the observation that anoikis resistant cells express higher
levels of SRSF3. These findings suggest that SRSF3 plays an important role in metastatic
behavior of tumors. Our initial findings provide us with potential future directions to
continue to investigate. If proven as a viable mechanism, therapies altering the action of
SRSF3, and therefore CPEB2 could provide an effective alternative or complement to
existing cancer treatments.
Initially, the observation that CPEB2 alternative splicing is altered in cancer
provided a direction for investigation. Now, with the understanding that SRSF3 controls
this interaction, there are even more possible directions to investigate. The most
important next step is to determine if reduction in SRSF3 expression translates to a
measurable difference in a metastatic phenotype. We can measure this in a number of
ways, by either analyzing cell growth or resistance to apoptosis. We could measure cell
growth using a proliferation assay or by measuring cell doubling rates in culture. After
promoting apoptosis, methods to measure cell resistance to apoptosis include: Western
Blot expression of apoptotic proteins such as caspase 3, caspase 8, cleaved PARP, and
cytoplasmic cytochrome c; flow cytometry sorting via Annexin-V and 7-AAD; luciferin
fluorescence assays; or post-apoptosis colonization assays.

30

CHAPTER 3
MEASURING METASTATIC EFFECT OF SRSF3

3.1 Introduction
After observing that SRSF3 plays a role in CPEB2 alternative splicing in TNBC,
the next step is to see if its reduction causes larger scale changes in cell functionality. As
described earlier, there are a number of methods to investigate cellular functionality
without use of an in vivo model. Lack of an in vivo model allows one to acquire results
quickly and often without the complications that can arise by using an animal model.
Therefore, we chose to use flow cytometry and western blot assays to measure the
metastatic function of cells with reduced SRSF3.

3.2 Materials and Methods
3.2.1 Cell culture
We acquired MDA MB 231 parental TNBC cells (231 Par) from ATCC. They were
cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen) and 1% penicillin/streptomycin (BioWhittaker) at 5% CO2 and at 37°C. When
the 231 Par cells reached 70% confluence, they were passaged to a maximum passage
number of 9. We acquired MDA MB 231 anoikis resistant TNBC cells (231 AnR) by plating
231 Par cells on 10cm2 culture dishes coated with 20 mg/mL poly(2-hydroxyethyl
methacrylate) (polyhema) (Sigma-Aldrich) for at least 3 passages on polyhema-coated
plates.
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3.2.2 Flow cytometry anoikis resistance assay
To measure the effect of SRSF3 reduction on TNBC cell resistance to anoikis, we
plated 1.5 X 105 231 Par, 231 AnR, 231 pcDNA, or 231 CPB on 6-well tissue culture
plates (Costar). After 24 hours, cells were treated with siRNA targeting nonsense
sequences (siCon) or SRSF3 (siSRSF3) for 6 hours, after which we replaced the media.
After an additional 24 hours, we replated these cells on 24-well tissue culture plates
(Costar) that were either nontreated (NT) or coated with polyhema (PH). The cells grew
overnight (12 hours) and then both the cells and media were collected for analysis.
In order to analyze cell death via flow cytometry, we resuspended and washed the
cells in a 1X Binding Buffer (eBioscience). Next, the pellet was resuspended in staining
buffer (1X Binding Buffer, 7-AAD, and Annexin-V). We let the cells sit covered on ice for
15 minutes. Following staining, the staining reaction was neutralized by adding additional
1X Binding Buffer. While on ice, we brought the samples to the VCU Flow Cytometry
Core. Samples were gated by Forward and Side Scatter detectors, then grouped them
into regions based on the 7-AAD and Annexin-V signals. Samples were run in triplicate
and statistically analyzed using ANOVA.

32

3.3 Results
3.3.1 Flow Cytometry Anoikis Resistance Assay
The first method that we used to analyze the effects of SRSF3 knockdown in TNBC
cells was to determine the portions of the cell population that were undergoing apoptosis
after treatment on polyhema-coated plates (Figure 3-1). This technique causes normal
cells to die due to anoikis (detachment-induced cell death). Cells that have undergone
mutation promoting metastasis will not appear positive for 7-AAD or Annexin-V due to
their developed resistance to anoikis.
7-AAD is a fluorescent dye that binds to double-stranded DNA [28]. When cells
undergo late apoptosis the plasma membrane starts to fall apart, resulting in the release
of usually contained double-stranded DNA. Annexin-V is a fluorescent dye that binds to
phosphatidylserine, which are usually located on the cytosolic side of the plasma
membrane due to enzymatic flippase activity [28]. However, when cells undergo
apoptosis, they cease flippase activity, resulting in the extracellular presentation of
phosphatidylserine. Both signals are indicative of apoptotic cells and can act as a
measure of cell viability. Thus, by gating for 7-AAD and Annexin-V signal, we can count
the percentage of the cell population that is undergoing apoptosis (Figure 3-2).
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Plate cells
24 hrs

Transfect with
siRNA
24 hrs

Transfer to
polyhema
coated plates
3-24 hrs

Analyze cell
death via flow
cytometry

Figure 3-1. Metastatic Effect Experimental Workflow. In order to properly study cell
resistance to apoptosis, we developed a method to accurately measure the influence of
SRSF3 on anoikis. As shown in the schematic above, 231 Par or 231 AnR cells are plated
on a 6 well plate (2 x 105 cells/well). After 24 hours, the cells are transfected with siRNA
(25 nM) for 6 hours, and then media was replaced. After another 24 hours, the cells are
transferred to polyhema-coated plates to stimulate apoptosis. Depending on the state of
apoptosis to study, cells can be collected after 3-6 hours (early apoptosis) or after 18-24
hours (late apoptosis).
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Figure 3-2. Sample Flow Cytometry Plot. After collection of a cell population, flow
cytometry analysis is performed to quantify the proportion of the population that
expresses particular fluorescent markers. The x-axis represents Annexin-V, an indicator
of early apoptosis. The y-axis represents 7-AAD, an indicator of late apoptosis/necrosis.
The gates were set to distinguish between apoptotic cells (Q2 and Q3) and living cells
(Q3). Comparison of population proportions indicate resistance to apoptosis.
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Following the protocol as described in section 3.2.3, we first looked at 231 Par and
231 AnR cells treated with control siRNA (siCon) or targeted siRNA (siSRSF3).
Comparing the apoptotic cell populations between the treatment conditions showed a few
notable things (Figure 3-3). First, 231 Par cells showed significantly higher basal levels
of apoptosis when plated on polyhema-coated plates. This was expected, as part of the
transformation process to create 231 AnR cells involves growth on polyhema-coated
plates. Additionally, we observed that knockdown of SRSF3 increased the amount of cell
death in both cell lines. This suggests that SRSF3 does account for some of the
resistance to anoikis in TNBC cells. Furthermore, the 231 AnR cells anoikis sensitivity
was restored to that of the pre-transformed 231 Par cell line with siSRSF3 treatment. This
suggests that alteration of SRSF3 may have been one of the mutations acquire to produce
the 231 AnR cell line initially.
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Figure 3-3. Reduction of SRSF3 Causes Increased Sensitivity to Anoikis. We
graphed the cells counted via flow cytometry and compared experimental groups. As
shown in Figure 3-2, we used the 7-AAD and Annexin-V markers for apoptosis to we gate
populations with sufficient signal. Populations above the gated threshold for Annexin-V
and 7-AAD were considered apoptotic and counted for the purpose of these data. Data
shown are representative of n = 3. Error bars indicate 1/2 standard deviation.
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3.4 Discussion
Looking into the effects of knocking down SRSF3 in metastatic TNBC cells
provided us with some very interesting insights into signaling pathways altered in cancer.
As determined previously, SRSF3 does influence the alternative splicing of CPEB2.
However, this observation is not clinically useful unless it can be utilized as a drug target
for potential patient treatment. To determine that, we used siRNA to knock down SRSF3
in cellular models of TNBC. Through use of numerous methods, we measured the
metastatic function of the cells when modulating levels of SRSF3. Our results showed
that reduction of SRSF3 causes an increase in cellular sensitivity to apoptosis.
Additionally, cells with greater resistance to apoptosis tend to overexpress SRSF3. These
observations suggest that SRSF3 is critical in cellular resistance to anoikis.
Our data suggest that this anoikis resistance was developed through alternative
splicing of CPEB2 into the more metastatic isoform, CPEB2B. Since endogenous
expression of CPEB2B did not influence anoikis resistance in our experiments, we
hypothesize that SRSF3 controls this action by promoting inclusion of exon 4 of CPEB2.
This allows CPEB2B to activate cellular signaling that promotes enhanced cellular growth
and inhibit apoptotic signaling. The mechanism through which this occurs is not yet
known, but is a future area of investigation.
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